Harbeck Nadia
Breast Center, Department of OB&GYN, University of Munich (LMU) Munich, Germany.
Curr Opin Obstet Gynecol. 2018 Feb;30(1):55-59. doi: 10.1097/GCO.0000000000000431.
Breast cancer is the most common malignancy in women and HER2-positive disease comprises about 15% of all breast cancer cases. Over the last few years, substantial advances have been made in treatment of early breast cancer (EBC) and advanced (ABC) HER2-positive (HER2+) breast cancer. The present review summarizes the major publications on HER2+ breast cancer in the year 2017 and discusses their clinical relevance.
The clinically most relevant data in 2017 relates to the EBC setting. The St. Gallen Consensus 2017 for the first time recommended neoadjuvant treatment as standard of care in HER2+ EBC. Moreover, the APHINITY trial demonstrated efficacy of adjuvant dual antibody-based HER2 blockade. Data in MBC mostly confirmed established treatment strategies.
Clinical data presented in 2017 for HER2+ breast cancer confirmed current guidelines and extended treatment options for patients. First intriguing steps were made towards de-escalation in the EBC setting.
乳腺癌是女性中最常见的恶性肿瘤，HER2阳性疾病约占所有乳腺癌病例的15%。在过去几年中，早期乳腺癌（EBC）和晚期（ABC）HER2阳性（HER2+）乳腺癌的治疗取得了重大进展。本综述总结了2017年关于HER2+乳腺癌的主要出版物，并讨论了它们的临床相关性。
2017年临床上最相关的数据与EBC情况有关。2017年圣加仑共识首次推荐新辅助治疗作为HER2+ EBC的标准治疗。此外，APHINITY试验证明了基于双抗体的辅助HER2阻断的疗效。MBC中的数据大多证实了既定的治疗策略。
2017年公布的HER2+乳腺癌临床数据证实了当前指南，并为患者扩展了治疗选择。在EBC情况下朝着降级治疗迈出了最初引人关注的步伐。
